Summary
Outlines health-agency priorities for safe clinical AI adoption through patient control and disclosure, interoperable data, risk-based market authorization, postmarket monitoring and outcomes-based payment.
Healthcare Implications
Health systems, developers and payers can track prospective changes to clinical evidence, monitoring, interoperability and reimbursement across FDA, CMS and HHS programs. The roadmap describes agency priorities and potential policy changes.